Phyton has developed a cell-based thapsigargin production method for Inspyr

By Gareth Macdonald

- Last updated on GMT

iStock/Zaharia_Bogdan
iStock/Zaharia_Bogdan

Related tags Clinical trial Pharmacology Drug discovery

Phyton Biotech has developed a cell based way of making thapsigargin, a cytotoxic plant extract that is being developed for the treatment of cancer by Inspyr Therapeutics.

Canada-based Phyton converted the thapsia​ garganica​ plant, from which thapsigargin is derived, into a fermentable cell line.

Thapsigargin is used to produce 12ADT, which is the active component of an investigational prodrug called mipsagargin that is being developed for the treatment of cancer by US biotechnology firm Inspyr Therapeutics.

The ability to synthesise the compound in culture will be of benefit to Inspyr spokesman, Tim Tennant, who told us the higher yields will be used to support further clinical development and commercial supply.

Mipsagargin has been studied in a Phase II​ trial in patients with liver cancer and has been granted Orphan Drug designation by the US Food and Drug Administration (FDA) in this indication.

Tennant also confirmed Phyton will supply Inspyr for trials and, if mipsagargin is approved, commercial production.

API production via fermentation

Phyton’s approach is to harvest undifferentiated cells – called callis – from source plants.

These cells are the screened to identify high producing lines that can be grown in cell culture.

The technology has been applied to the production of paclitaxel, for which Phyton was granted a Certificate of suitability to European Pharmacopeia (CEP)​ in 2012​.

The firm claims to produce 500kg of paclitaxel each year at its facility in Vancouver.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...